final, what stood out to me is opportunity for sho

final, what stood out to me is opportunity for short term significant gov money later in q4 from emergency preparedness funds at NHHS and it sounds to me like gameplan now is to focus on ESS until they sell MSPrecise, which sounds pretty much sold, in q4. Post MSprecise sale, sounds like they'll try uplist attempt #2 and then Eltoprazine study can start again and we'll be back on track with money in the bank.



in addition, once ESS starts trials we'll have data coming in every week. should provide many catalyst opportunities and it seems ESS could be way bigger than we imagine with offshoot applications and selling a coupon for accelerated regulatory review to other pharmas for hundreds of millions.

GC suggested MANF data on Parkinsons and other indications would come out shortly and they're looking at ways to get the Parkinsons program going MANF "golden child... multiple billions of revenue...protecting... shepherd"

CTE data from lympro could help unify neurodegenesis theories. Again ,company targets cell biology way upstream of these other manifested disease indicators like plaques tau etc.